THOUSANDS of lung cancer patients will have access to potentially life-saving immunotherapy cancer drugs, following a ruling by European health chiefs. The announcement, made last week by the European Commission, was prompted by a trial which showed that over two years patients with advanced lung cancer were 51 per cent more likely to survive with immune-boosting drugs than by standard treatment – at least doubling their 12-month life expectancy.
You Can See More: Cancer drug victory as thousands benefit
The following article Cancer drug victory as thousands benefit is courtesy of Daily Express :: Health Feed
THOUSANDS of lung cancer patients will have access to potentially life-saving immunotherapy cancer drugs, following a ruling by European health chiefs. The announcement, made last week by the European Commission, was prompted by a trial which showed that over two years patients with advanced lung cancer were 51 per cent more likely to survive with immune-boosting drugs than by standard treatment – at least doubling their 12-month life expectancy.
THOUSANDS of lung cancer patients will have access to potentially life-saving immunotherapy cancer drugs, following a ruling by European health chiefs. The announcement, made last week by the European Commission, was prompted by a trial which showed that over two years patients with advanced lung cancer were 51 per cent more likely to survive with immune-boosting drugs than by standard treatment – at least doubling their 12-month life expectancy.
0 comments:
Post a Comment
Note: Only a member of this blog may post a comment.